Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias — Stella

Recruiting

Back to Leukemia, Lymphocytic, Chronic, B-Cell trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Early testing / Safety & dosing

Sponsor

National Cancer Institute (NCI)

Enrollment target

~132 participants

Started

September 2024

Primary completion

July 2029

Age range

18 Years – 120 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov